Literature DB >> 7827180

Excellent technique survival on home peritoneal dialysis: results of a regional program.

K K Jindal1, D J Hirsch.   

Abstract

OBJECTIVE: To examine peritoneal dialysis technique survival in our regional, continuous ambulatory peritoneal dialysis (CAPD) program.
DESIGN: Retrospective analysis.
SETTING: Tertiary care dialysis program at an academic medical center. PATIENTS: 155 patients representing all those in the peritoneal dialysis program between October 1, 1987 and October 1, 1990. OUTCOME MEASURES: The study analyzed patient and technique survival as well as the reasons for discontinuation of dialysis. In addition, the incidence and type of peritonitis and exit-site infection were also analyzed.
RESULTS: Three-year actuarial patient survival was 66% and three-year technique survival was 86%, with data censored for death and transplant patients. Fifty-seven percent of transfers to hemodialysis were due to peritonitis, usually fungal or multiorganism bacterial. Only 1 patient failed due to exit-site and tunnel infection, and 1 due to inadequate dialysis. The catheter removal rate was 0.04 per patient-year.
CONCLUSIONS: Excellent CAPD technique survival can be achieved if exit-site and tunnel infection rates are low.

Entities:  

Mesh:

Year:  1994        PMID: 7827180

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  2 in total

1.  Benefits of low dose immunoglobulin in the treatment of refractory CAPD peritonitis and longevity of technical survival on CAPD.

Authors:  Belda Dursun; Murat Tuncer; Rasih Felek; F Fevzi Ersoy
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  Tumor-killing nanoreactors fueled by tumor debris can enhance radiofrequency ablation therapy and boost antitumor immune responses.

Authors:  Zhijuan Yang; Yujie Zhu; Ziliang Dong; Wei Li; Nailin Yang; Xianwen Wang; Liangzhu Feng; Zhuang Liu
Journal:  Nat Commun       Date:  2021-07-14       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.